Leading Health and Life Sciences in Nova Scotia

Entrevestor: Densitas Breast Density Tool In PEI

Halifax-based Densitas, whose software helps assess the density of breasts during mammograms, has announced that Prince Edward Island has become the second province, after Nova Scotia, to integrate its software across its screening program.

The Densitas software — named Densitas densityai —  provides an automated mechanism for quantifying and recording breast tissue density, a risk factor for breast cancer in women. Dense breasts can mask cancerous cells. Dense breast tissue is also linked to higher chances of cancer.

Now, every woman who receives a screening mammogram on P.E.I. will be notified of her​ breast density through the company’s densityai algorithm.

“Our advanced solutions are built to solve real clinical problems and effectively support healthcare providers,” said Ryan Duggan, Director of Product Development at Densitas in a statement.

The Densitas platform comprises three different products that tackle challenges in breast cancer screening, including mammography quality, workflow efficiencies, compliance with national standards, and meeting accreditation requirements.

ENTREVESTOR – Densitas Joins Nuance Marketplace

See original Entrevestor article here

Halifax-based Densitas Inc. whose software helps assess the density of breasts during mammograms, announced this week its densitas densityai software will soon be available on the Nuance AI Marketplace.

In a statement, Densitas said the Nuance marketplace provides access to more than 70 percent of all radiologists across the largest network of connected healthcare facilities in the U.S.

“AI can play an important supporting role for radiologists by automating routine, time-consuming, subjective and fatiguing tasks so that they can focus on more challenging interpretive tasks,” said Woojin Kim, chief medical information officer at the Healthcare Division of Nuance Communications.

“What sets densitas densityai apart is that it has been thoughtfully designed to process routinely archived mammograms so that breast density assessments can be obtained from historical studies when comparing current with prior exams.”

Densitas densityai delivers automated breast density assessments from standard digital imaging in the medical community. The Densitas software provides an automated mechanism for quantifying and recording breast tissue density, a risk factor for breast cancer in women. Dense breasts can mask cancerous cells. Dense breast tissue is also linked to higher chances of cancer.

As well as speeding and simplifying the process of quantifying breast density, the Densitas technology standardizes the density measurement and enables stratification of women to ensure those who need more aggressive follow-up receive it.

Approved by the Food and Drug Administration, the densitas densityai solution uses artificial intelligence to align with how the human eye processes breast images in mammograms. It rapidly generates reproducible and standardized breast density assessments.

Densitas recently announced that densitas densityai has also been selected for use in a major breast screening trial in Germany.

Densitas Software Wins Procurement For DIMASOS Breast Screening Trial In Germany

See original news release here

Announcing our densitas densityai™ software will be deployed in up to 24 clinics throughout Germany as part of a procurement for a major breast cancer screening trial.

Our software will be used to provide breast density measurements at point of care to identify women for supplemental breast cancer screening as part of the DIMASOS 2 Trial.The announcement highlights not just the importance to this trial of the software’s unique ability to process prior ‘for presentation’ mammograms from a wide range of scanner vendors, but to any practical clinical deployment.

What is the objective of the trial?

The trial will aim to establish whether combined mammography and ultrasound exams can improve early breast cancer detection. It will also explore if this can be done feasibly and cost-effectively in standard screening workflow.

Who is leading the trial?

The trial will be led by Prof. Dr. Sylvia H. Heywang-Köbrunner, M.D., Head of Referenzzentrum Mammographie München, internationally recognized for her pioneering work in contrast-enhanced breast MRI and modern biopsy procedures.

She will be using densitas densityai™ breast density measures to establish a supplemental ultrasound screening protocol in the DIMASOS 2 trial.

When asked about the trial, Dr. Heywang-Köbrunner said:

“Women with dense breasts are subject to the masking effect of mammographic density and its association with breast cancer risk. The objective of the DIMASOS 2 trial is to test whether combined mammography/ultrasound exams can improve early cancer detection and if this can feasibly and cost effectively be done in routine screening workflow.

The unique ability of the Densitas® software to analyze prior ‘for presentation’ mammograms from a wide range of mammography scanner vendor models is pivotal to this trial and is important for any practical clinical deployment.” 

What is our densitas densityai™ software used for?

Our densitas densityai™ software delivers fully automated, standardized, and reproducible breast density assessments from standard DICOM clinical use mammograms.

Results from densitas densityai™ are generated by two distinct algorithms that decouple the breast density assessment into quantitative and qualitative scales in alignment with the ACR BI-RADS 4th and 5th edition density classification system.

These results can be incorporated into breast cancer risk models to provide standardized and reproducible patient-specific risk estimates.

Mo Abdolell, CEO of Densitas, had this to say about the procurement:

“Being selected as the vendor of choice to provide automated breast density assessment for the DIMASOS 2 Trial attests to our modern AI-driven technology superseding dated breast density algorithms developed prior to the introduction of the ACR BI-RADS 5th ed. density scale in 2013.

Densitas densityai™ processes the same clinical use images that radiologists examine, setting it apart by enabling seamless PACS-centric integrations and retrospective auditing capabilities of routinely archived exams. This makes it an ideal fit for the DIMASOS 2 trial.

More broadly this also simplifies clinical deployments, and is more cost effective and deeply integrated into radiologist reporting workflows with key applications and platforms that include Nuance PowerScribe One and PowerScribe 360 Reporting, The Nuance AI Marketplace, Blackford Platform and Curated Marketplace,  Ikonopedia structured breast reporting and tracking software, TeraRecon’s AI interoperability platform, EnvoyAI, and Three Palm Software’s WorkstationOne.”

Get in touch with our team

Interested in learning more about how our suite of solutions for digital mammography  is helping move the needle in breast cancer screening?

Schedule a demo with a member of our sales team to get a tailored walkthrough of our entire suite of solutions offered as part of the densitasai™ platform.

ENTREVESTOR: Medteq Backs Densitas, Spring Loaded

Read the full Entrevestor article here

Two Halifax-area medtech companies – Spring Loaded Technology and Densitas – have received a slice of an $11 million equity funding exercise anchored by the Montreal-based health technology organization Medteq.

Medteq, which nurtures Canadian health-technology innovators, issued a statement saying that its $14 million investment fund made its first investments, backing eight companies based in Montreal and Halifax. MEDTEQ invested alongside co-investors including: Anges-Quebec, Anges-Quebec Capital, Innovacorp, Real Ventures and others.

The target companies included Spring Loaded, which makes advanced knee braces, and Densitas, which assesses the density of breast tissue during mammograms. Innovacorp, the Nova Scotia government’s early-stage venture capital agency, was already an existing investor in both companies.

Entrevestor: Densitas Partners with U.S. Beta User

Halifax-based breast imaging analytics company Densitas has announced a collaboration with TeleMammography Specialists of Decatur, Georgia, that will improve the quality of breast screening offered to more than 60,000 women annually.
TeleMammography Specialists is an international teleradiology services provider and will be the first U.S. beta user for the new densitasquality solution, the company said in a statement. The product will improve the communications and information sharing needed to meet FDA guidelines.
TeleMammography Specialists also plan to implement the recently released densitasdensity automated breast density assessment software.
“Our goal is to provide tools that reduce the documentation, process and communication burdens of meeting EQUIP (FDA) guidelines and enables sustainable delivery of quality assurance across the mammography enterprise,” Mohamed Abdolell, CEO of Densitas, said in the statement.

See full article here

Densitas Enters Platform Partnership with Blackford

PRNewswire/ – Densitas, Inc., a breast imaging analytics innovator based in Halifax, Nova Scotia, today announced the signing of a new Alliance Partner Agreement with Blackford. This agreement gives Blackford the right to promote, market, sell, distribute, and license densitasdensity™ directly via integration with the Blackford Platform™. Work will now commence to integrate densitasdensity™ with the Blackford Platform. “The platform approach will help us bring new products to market more quickly, support our scaling activities, and simplify integration for our customers” says Mohamed Abdolell, CEO of Densitas. “We expect the Blackford Platform to reduce our time to market and shorten our sales cycle as we will be incorporated as an extension of the Blackford Platform infrastructure.” The densitasdensity™ software provides an automated mechanism for quantifying and recording percent breast tissue density, and making it readily available to the radiologist. Beyond speeding and simplifying the process of quantifying breast density, densitasdensity™ standardizes the density measurement which enables uniform application of risk-based stratification of screen eligible women aimed at ensuring those who need more aggressive follow-up receive it, while those who do not need aggressive follow-up do not receive unnecessary imaging. Densitas software is unique in that it assesses breast density using the routinely archived processed DICOM images that radiologists normally review, and therefore supports prospective and retrospective breast density measurement for clinical care and for research. Blackford CEO, Ben Panter said this of the alliance: “We are delighted to add densitasdensity™ to the curated marketplace of applications available through Blackford Platform. We look forward to working with Densitas to provide our customers and channel partners multiple imaging applications that can be easily deployed and maintained.” densitasdensity™ will be demonstrated at the upcoming Radiological Society of North America (RSNA) 2018 annual meeting in Chicago. Densitas personnel will be available to discuss the benefits and capabilities of density in Booth #3274 – South Hall at RSNA and in the machine learning pavilion, Kiosk #7367W – North Hall. To learn more about Blackford Platform applications including densitasdensity™, book a demo at RSNA or visit Blackford at Booth #7364. About Densitas: Densitas’ vision is to move the needle in breast cancer screening through tailored patient management for sustainable healthcare service delivery and improved outcomes. Densitas develops advanced breast imaging analytics technologies powered by machine learning with the goal to deliver on-demand actionable insights that improve the quality of breast health management. Our products tackle the key challenges facing women’s imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines, and delivery of appropriate care at sustainable costs. Learn more at www.densitas.health and in our virtual press kit. About Blackford Blackford provide a single platform to quickly access and manage a curated marketplace of regulatory approved medical image analysis applications and AI algorithms that add clinical value. Easily integrated into existing workflows, the platform provides actionable information that allows healthcare providers to use imaging information smartly and reduce the cost of care, while improving diagnostic confidence and patient outcomes. Founded in 2010, and with operations in the United Kingdom and the United States, Blackford Analysis is backed by TRI Cap, Old College Capital, and Archangel Investors, one of the UK’s leading business angel syndicates. For more information, visit www.blackfordanalysis.com Contact Information: Media Contact Densitas: Alex Morris [email protected] 647-470-4363 Media Contact Blackford: Greg Kingston [email protected] +44 131 6688 411]]>